Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Lipid Absorption01:24

Lipid Absorption

708
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
708
Operant Conditioning Intervention01:24

Operant Conditioning Intervention

112
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
112
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

2.4K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Harnessing Large-Scale Multi-Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts.

JAMA internal medicine·2026
Same author

Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study.

PLoS medicine·2026
Same author

Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization.

Communications medicine·2026
Same author

Association of Reduction in Continuity of Care During COVID-19 Pandemic With Cardiovascular Diseases, Kidney Failure and All-Cause Mortality for People With Diabetes: A Cohort Study in Hong Kong.

Diabetes, obesity & metabolism·2026
Same author

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026

関連する実験動画

Updated: Sep 10, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

強化学習による長期的な疾病予防の最適化:精密な脂質コントロールの枠組み

Yekai Zhou1,2,3, Ruibang Luo4,5,6, Joseph Edgar Blais7

  • 1Department of Computer Science, School of Computing and Data Science, The University of Hong Kong, Hong Kong SAR, China.

NPJ digital medicine
|August 27, 2025
PubMed
まとめ

Duramaxは新しいAIフレームワークで 現実世界のデータを分析することで 慢性疾患の予防を最適化します 心血管疾患 (CVD) のリスク軽減戦略を改善し,個別化され,透明性の高い勧告を提供しています.

さらに関連する動画

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.9K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

関連する実験動画

Last Updated: Sep 10, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.9K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

科学分野:

  • コンピュータ医学
  • 医療における人工知能
  • 予防的な心臓病

背景:

  • 慢性疾患の予防には 短期的な治療目標を超えて 適応的な戦略が必要です
  • 現在のアプローチでは 患者の長期的な生存軌跡に関する 総合的な洞察が欠けています
  • パーソナライズされた医療は 予防的なケアを最適化するために 先進的な分析ツールを必要とします

研究 の 目的:

  • 証拠に基づいた強化学習の枠組みであるDuramaxを紹介します
  • 慢性疾患の長期的な予防戦略を最適化し,心臓血管疾患 (CVD) に焦点を当てます.
  • 医療記録の計算分析を通じて 個別化された疾病予防を強化する.

主な方法:

  • デュラマックス (Duramax) という 強化学習の枠組みを 開発しました
  • 200種類以上の脂質調節薬と 360万ヶ月の治療を対象とした 広範なデータセットが利用されました
  • 2970万ヶ月の独立コホートでDuramaxの効果を検証した.

主要な成果:

  • デュラマックスは93の政策値を達成し,臨床医を大幅に上回った (68の値).
  • デュラマックスの推奨事項に準拠すると,臨床実験で心血管疾患のリスクは6%減少しました.
  • 後期分析により,Duramaxの意思決定プロセスは透明で合理的であることが確認されました.

結論:

  • デュラマックスは,心臓血管疾患の長期的な予防戦略の最適化において優れた性能を示しています.
  • 医療記録のパーソナライズされた計算分析により 細かい病気の予防が可能になります
  • 慢性疾患の管理における患者の成果を 大きく改善できます